M. Houshmand, G. Simonetti, and P. Circosta, Chronic myeloid leukemia stem cells, Leukemia, vol.33, pp.1543-1556, 2019.

M. W. Deininger and B. J. O'brien-druker, International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib, Blood, vol.114, p.1126, 2009.

H. Kantarjian, F. Giles, and L. Wunderle, Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL, N Engl J Med, vol.354, pp.2542-2551, 2006.

M. Talpaz, N. P. Shah, and H. Kantarjian, Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias, N Engl J Med, vol.354, pp.2531-2541, 2006.

J. E. Cortes, H. Kantarjian, and N. P. Shah, Ponatinib in refractory Philadelphia chromosome-positive leukemias, N Engl J Med, vol.367, pp.2075-2088, 2012.

H. M. Kantarjian, N. P. Shah, and J. E. Cortes, Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION), Blood, vol.119, pp.1123-1129, 2012.

H. Bower, M. Bj?-orkholm, P. W. Dickman, M. H?-oglund, P. C. Lambert et al., Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population, J Clin Oncol, vol.34, pp.2851-2857, 2016.

S. M. Graham, H. G. Jørgensen, and A. E. , Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro, Blood, vol.99, pp.319-325, 2002.

J. C. Chomel and A. G. Turhan, Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and longterm dormancy, Oncotarget, vol.2, pp.713-727, 2011.

G. Etienne, J. Guilhot, and D. Rea, Long-term follow-up of the French Stop Imatinib (STIM1) Study in patients with chronic myeloid leukemia, J Clin Oncol, vol.35, pp.298-305, 2017.

J. C. Chomel, N. Sorel, J. Guilhot, F. Guilhot, and A. G. Turhan, BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia, Blood, vol.119, pp.2964-2965, 2012.

D. M. Ross, S. Branford, and J. F. Seymour, Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study, Blood, vol.122, pp.515-522, 2013.

A. C. Culhane, J. Thioulouse, G. Perriere, and D. G. Higgins, MADE4: an R package for multivariate analysis of gene expression data, Bioinformatics, vol.21, pp.2789-2790, 2005.
URL : https://hal.archives-ouvertes.fr/hal-00427730

S. Lê, J. Josse, and F. Husson, FactoMineR: an R package for multivariate analysis, J Stat Softw, vol.25, issue.1, 2008.

H. Wickham, Elegant Graphics for Data Analysis, 2009.

R. Tibshirani, T. Hastie, B. Narasimhan, and G. Chu, Diagnosis of multiple cancer types by shrunken centroids of gene expression, Proc Natl Acad Sci USA, vol.99, pp.6567-6572, 2002.

C. Trapnell, D. Cacchiarelli, and J. Grimsby, The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells, Nat Biotechnol, vol.32, pp.381-386, 2014.

K. Cramer-morales, M. Nieborowska-skorska, and K. Scheibner, Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile, Blood, vol.122, pp.1293-1304, 2013.

D. Perrotti, C. Jamieson, J. Goldman, and T. Skorski, Chronic myeloid leukemia: mechanisms of blastic transformation, J Clin Invest, vol.120, pp.2254-2264, 2010.

A. S. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M. W. Deininger et al., Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity, J Clin Invest, vol.121, pp.396-409, 2011.

S. Katagiri, T. Tauchi, and S. Okabe, Combination of ponatinib with hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia, Clin Cancer Res, vol.19, pp.1422-1432, 2013.

C. Zhao, A. Chen, and C. H. Jamieson, Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia, Nature, vol.458, pp.776-779, 2009.

E. A. Nelson, S. R. Walker, and E. Weisberg, The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors, Blood, vol.117, pp.3421-3429, 2011.

K. Ito, R. Bernardi, and A. Morotti, PML targeting eradicates quiescent leukaemia-initiating cells, Nature, vol.453, pp.1072-1078, 2008.

Y. Chen, Y. Hu, H. Zhang, C. Peng, and S. Li, Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia, Nat Genet, vol.41, pp.783-792, 2009.

I. Cobo, P. Martinelli, and M. Fl, Transcriptional regulation by NR5A2 links differentiation and inflammation in the pancreas, Nature, vol.554, pp.533-537, 2018.

S. Darmanis, S. A. Sloan, and D. Croote, Single-cell RNA-Seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma, Cell Rep, vol.21, pp.1399-1410, 2017.

A. Giustacchini, S. Thongjuea, and N. Barkas, Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia, Nat Med, vol.23, pp.692-702, 2017.

V. Hovestadt, K. S. Smith, and L. Bihannic, Resolving medulloblastoma cellular architecture by single-cell genomics, Nature, vol.572, pp.74-79, 2019.

X. Ma, Y. Liu, and Y. Liu, Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours, Nature, vol.555, pp.371-376, 2018.

R. Warfvinge, L. Geironson, and M. Sommarin, Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML, Blood, vol.129, pp.2384-2394, 2017.

S. R. Viswanathan, J. T. Powers, and W. Einhorn, Lin28 promotes transformation and is associated with advanced human malignancies, Nat Genet, vol.41, pp.843-848, 2009.

M. Ahmed, I. Dusanter-fourt, and A. Dugray, BCR-ABL fails to inhibit apoptosis in U937 myelomonocytic cells expressing a carboxyl-terminal truncated STAT5, Leuk Lymphoma, vol.42, pp.445-455, 2001.

C. Walz, W. Ahmed, and K. Lazarides, Essential role for Stat5a/ b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice, Blood, vol.119, pp.3550-3560, 2012.

L. Casetti, S. Martin-lanner-ee, and I. Najjar, Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells, Cancer Res, vol.73, pp.2052-2058, 2013.

A. G. Turhan, STAT5 as a CML target: STATinib therapies?, Blood, vol.117, pp.3252-3253, 2011.

P. Valent, Targeting the JAK2-STAT5 pathway in CML, Blood, vol.124, pp.1386-1388, 2014.

W. Warsch, C. Walz, and V. Sexl, JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia, Blood, vol.122, pp.2167-2175, 2013.

T. O'hare, M. S. Zabriskie, A. M. Eiring, and M. W. Deininger, Pushing the limits of targeted therapy in chronic myeloid leukaemia, Nat Rev Cancer, vol.12, pp.513-526, 2012.

M. Dolinska, A. Piccini, and W. M. Wong, Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34 + CD38 ? stem and progenitor cells in chronic myeloid leukemia, Biochem Biophys Res Commun, vol.490, pp.378-384, 2017.

C. M. Lucas, R. J. Harris, A. Giannoudis, E. Mcdonald, and R. E. Clark, Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia, Haematologica, vol.99, pp.1710-1715, 2014.

P. Gallipoli, A. Cook, and S. Rhodes, JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo, Blood, vol.124, pp.1492-1501, 2014.